Study

EORTC-26053-22054

Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON intergroup trial.

Study documentation Back to result

Trial Status

All trial activities ended

Dates

Date of activation: 03-Dec-2007
Date Step1 close: 16-Sep-2015
Date Step2 close: 06-Oct-2015

Data management at EORTC

Yes

Design

Phase 3
Randomized open label

Targeted Sample size

EORTC Groups: 550 - All Groups: 748

Protocol summary

http://clinicaltrials.gov/study/NCT00626990

NCT number

NCT00626990

EudraCT

2006-001533-17

Study

EORTC-26053-22054-CATNON

Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON intergroup trial.

Study documentation Back to result

Research Projects

RP-1626-QLG

Predictors of quality of life ratings from patients with primary brain tumors: the role of self-awareness and cognitive functioning

RP-2560-TRIAL-GEN

Reforming Clinical TRIAL Eligibility for Improved GENeralisability – A Multifaceted-Study on EORTC Protocols, Investigator's Survey, Screening Data, and Real-world Evidence